ArticleTurkish journal of haematology : official journal of Turkish Society of Haematology2026
Establishment of a Multimodal Prognostic Prediction Model for Multiple Myeloma Patients Based on Radiomics and Clinical Features: A Retrospective Cohort Study
Article in Turkish journal of haematology : official journal of Turkish Society of Haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: We aimed to develop a survival prediction system integrating radiomics and clinical features for newly diagnosed multiple myeloma (MM) and to compare the performance of different feature sets and algorithms in the early prediction of progression-free survival (PFS). Materials and Methods: This study retrospectively included 300 MM patients between June 2022 and June 2024, with their baseline positron emission tomography, computed tomography, and magnetic resonance imaging radiomics features and clinical variables collected. Following construction of a radiomics-based risk score (Rad-score), seven machine learning-based survival models were established using the clinical feature set, the image feature set, and the integrated feature set. Results: The fusion feature set-based gradient boosting model (GBM) showed numerically favorable overall performance in predicting 12-month PFS, suggesting that the integration of radiomics and clinical variables may provide complementary predictive information for early risk stratification. The model effectively distinguished high-, intermediate-, and low-risk patients (log-rank p<0.001), and calibration curve analysis and decision curve analysis revealed favorable calibration and high clinical net benefits. Shapley additive explanations analysis showed that the Rad-score was one of the most important features in the model, indicating that radiomics information may contribute prognostic value within the integrated feature space. β2-microglobulin, age, lactate dehydrogenase, blood calcium, platelet count, and hemoglobin were also identified as key contributing features. Conclusion: The integration of radiomics and clinical variables may improve early PFS prediction in MM patients. The GBM using fused features showed relatively good discriminative ability, potential clinical applicability, and favorable interpretability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.